EUVIMEDEUVIMED entdecken
Crossref

Disproportionality Signal Analysis of Cardiac Adverse Events Associated with Filgrastim and Pegfilgrastim using EudraVigilance and FAERS

Nitin Kumar, Mandeep Kumar Arora, Vivekanandan Kalaiselvan, Shivangi Rajput

International Journal of Drug Delivery Technology · 16.04.2026 · 16 (13s)

DOI: 10.25258/ijddt.16.13s.52 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 16.04.2026. Verfasst von Nitin Kumar und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Filgrastim and pegfilgrastim granulocyte colony-stimulating factors (G-CSFs) are widely used in oncology, yet their cardiac safety profiles need a systemic pharmacovigilance evaluation.

Objectives

To detect and compare cardiac adverse-event reporting signals for filgrastim and pegfilgrastim biosimilars using EudraVigilance and FAERS.

Methods

Disproportionality analyses were conducted from market authorization through 30 June 2024 in reports where filgrastim or pegfilgrastim biosimilars were recorded as suspect drugs and at least one Preferred Term (PT) under the System Organ Class (SOC) "Cardiac disorders". The top 30 cardiac PTs (highest reporting frequency within each database) were evaluated. Metrics included ROR with 95% confidence interval, PRR, χ², and IC025.

Results

EudraVigilance included 953 cardiac reports (filgrastim n=583; pegfilgrastim n=370) and identified three strong statistical signals: filgrastim-cardiotoxicity (ROR 28.32; 95% CI 1.710-469.014), filgrastim-pericarditis (ROR 2.49; 95% CI 1.005-6.179), and pegfilgrastim-cardiac disorder (ROR 2.52; 95% CI 1.346-4.705). FAERS included 2,020 drugassociated cardiac reports after exclusions and identified 12 strong signals. Concordant strong statistical signals across both databases were filgrastim-cardiotoxicity, filgrastim-pericarditis, and pegfilgrastim-cardiac disorder.

Conclusions

Dual-database signal detection identified three strong statistical signals within cardiac disorders, supporting prioritization for further validation in longitudinal healthcare datasets.

Zitieren

APA

Kumar, N., Arora, M. K., Kalaiselvan, V., & Rajput, S. (2026). Disproportionality Signal Analysis of Cardiac Adverse Events Associated with Filgrastim and Pegfilgrastim using EudraVigilance and FAERS. International Journal of Drug Delivery Technology, 16(13s). https://doi.org/10.25258/ijddt.16.13s.52

Vancouver

Kumar N, Arora MK, Kalaiselvan V, Rajput S. Disproportionality Signal Analysis of Cardiac Adverse Events Associated with Filgrastim and Pegfilgrastim using EudraVigilance and FAERS. International Journal of Drug Delivery Technology. 2026;16(13s). doi:10.25258/ijddt.16.13s.52

BibTeX
@article{Kumar2026,
  author = {Kumar, Nitin and Arora, Mandeep Kumar and Kalaiselvan, Vivekanandan and Rajput, Shivangi},
  title = {Disproportionality Signal Analysis of Cardiac Adverse Events Associated with Filgrastim and Pegfilgrastim using EudraVigilance and FAERS},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {13s},
  doi = {10.25258/ijddt.16.13s.52}
}
Kostenlos starten →